Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis
Corresponding Author
M.A. de Bièvre MD
Atrium Medical Center, Heerlen, Netherlands
Atrium Medical Centre, Henri Dunantstraat 5, Heerlen, 6419 PC, NetherlandsSearch for more papers by this authorA.H. Oberndorff-Klein Woolthuis MD
University Hospital, Maastricht, Netherlands
Search for more papers by this authorR.W. Stockbrügger MD
University Hospital, Maastricht, Netherlands
Search for more papers by this authorCorresponding Author
M.A. de Bièvre MD
Atrium Medical Center, Heerlen, Netherlands
Atrium Medical Centre, Henri Dunantstraat 5, Heerlen, 6419 PC, NetherlandsSearch for more papers by this authorA.H. Oberndorff-Klein Woolthuis MD
University Hospital, Maastricht, Netherlands
Search for more papers by this authorR.W. Stockbrügger MD
University Hospital, Maastricht, Netherlands
Search for more papers by this authorAbstract
Background: In several open and 1 controlled trial, unfractionated heparin was effective in the treatment of active ulcerative colitis (UC). Low molecular weight heparin (LMWH) had a similar effect in several open studies.
Methods: We studied the efficacy, safety, and tolerability of LMWH in mild to moderately active UC in a randomized, double-blind, placebo-controlled trial. In all, 29 patients with a mild or moderate recurrence of UC during salicylate treatment were randomized to receive either reviparin 3,436 IU (n = 15) subcutaneously twice daily or placebo (n = 14). The study period was 8 weeks. Treatment was discontinued if there was no improvement at 4 weeks or at any disease progression. Primary outcome measure was clinical improvement at 8 weeks measured by the Colitis Activity Index (CAI) and the Clinical Symptoms Grading (CSG, based on the CAI). Endoscopic and histologic grading and quality of life as measured by the Inflammatory Bowel Disease Questionnaire (IBDQ) were secondary outcome measures. Patients were closely monitored for adverse events.
Results: Twenty of 29 patients finished the 8-week treatment period (reviparin versus placebo: 11 versus 9; P = 0.70). There was no difference in CSG, CAI, endoscopic and histologic grading, or IBDQ. Treatment was well tolerated and no serious adverse events occurred.
Conclusion: In this study, treatment with LMWH showed no significant clinical advantage compared to placebo in mild to moderately active UC.
(Inflamm Bowel Dis 2007)
REFERENCES
- 1 Mendes de Leon C. [ The treatment of acute polyarthritis with heparin]. Ned Tijdschr Geneeskd. 1952; 96: 2417–2423.
- 2 Murav'ev Iu V, Samoilova SI. [ Heparin treatment of rheumatoid arthritis and systemic lupus erythematosus]. Ter Arkh. 1979; 51: 48–52.
- 3 Kartashov IA. [ Heparin in the complex treatment of rheumatoid arthritis]. Sov Med. 1977; 72–75.
- 4 Zavgorodnii LG, Mustiats AP. [ Use of anticoagulants in the combined treatment of nonspecific ulcerative colitis]. Klin Med (Mosk). 1982; 60: 74–80.
- 5 Gaffney PR, O'Leary JJ, Doyle CT, et al. Response to heparin in patients with ulcerative colitis. Lancet. 1991; 337: 238–239.
- 6 Gaffney PR, Doyle CT, Gaffney A, Hogan J, Hayes DP, Annis P. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol. 1995; 90: 220–223.
- 7 Panes J, Esteve M, Cabre E, et al. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology. 2000; 119: 903–908.
- 8 Ang YS, Mahmud N, White B, et al. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment Pharmacol Ther. 2000; 14: 1015–1022.
- 9 Folwaczny C, Wiebecke B, Loeschke K. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol. 1999; 94: 1551–1555.
- 10 Evans RC, Wong VS, Morris AI, Rhodes JM. Treatment of corticosteroid-resistant ulcerative colitis with heparin—a report of 16 cases. Aliment Pharmacol Ther. 1997; 11: 1037–1040.
- 11 Dotan I, Hallak A, Arber N, et al. Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig Dis Sci. 2001; 46: 2239–2244.
- 12 Torkvist L, Thorlacius H, Sjoqvist U, et al. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther. 1999; 13: 1323–1328.
- 13 Vrij AA, Jansen JM, Schoon EJ, de Bruine A, Hemker HC, Stockbrugger RW. Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi. Scand J Gastroenterol Suppl. 2001; 41–47.
- 14 Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989; 170: 2–6; discussion 16–19.
- 15
Truelove S,
Witts, LJ.
Cortisone in ulcerative colitis: final report on a therapeutic trial.
Br Med J.
1955;
2:
1042–1048.
10.1136/bmj.2.4947.1041 Google Scholar
- 16 Tytgat G. Comparison of two different oral Mesalazine formulations (Asacol versus Salofalk) in preventing relapses of ulcerative colitis: a dose-ranging, prospective randomized open blinded end-point (PROBE) study. Protocol “Asacol Probe Trial” 1993.
- 17 Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 330: 1841–1845.
- 18 Lamme SJ, de Rooij PD, Huijgens PC, Rauwerda JA. [ The HITT syndrome: heparin-induced thrombocytopenia and thrombosis as a cause of paradoxically occurring thromboembolisms]. Ned Tijdschr Geneeskd. 1994; 138: 189–193.
- 19 Slocum MM, Adams JG Jr, Teel R, Spadone DP, Silver D. Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome. J Vasc Surg. 1996; 23: 839–843.
- 20 Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989; 96: 804–810.
- 21 Day R, Ilyas M, Daszak P, Talbot I, Forbes A. Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Dig Dis Sci. 1999; 44: 2508–2515.
- 22 Yayon A, Gray TE, Zimmer Y, Eisenstein M, Givol D. Ligand binding by fibroblast growth factor receptors investigated using chimeric receptor molecules. J Recept Signal Transduct Res. 1995; 15: 185–197.
- 23 Spivak-Kroizman T, Lemmon MA, Dikic I, et al. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell. 1994; 79: 1015–1024.
- 24 Arai T, Parker A, Busby W Jr, Clemmons DR. Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. J Biol Chem. 1994; 269: 20388–20393.
- 25 Bannon PG, Kim MJ, Dean RT, Dawes J. Augmentation of vascular endothelial barrier function by heparin and low molecular weight heparin. Thromb Haemost. 1995; 73: 706–712.
- 26 Miller SJ, Hoggat AM, Faulk WP. Heparin regulates ICAM-1 expression in human endothelial cells: an example of non-cytokine-mediated endothelial activation. Thromb Haemost. 1998; 80: 481–487.
- 27 Bloom S, Kiilerich S, Lassen MR, et al. Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2004; 19: 871–878.
- 28 Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997; 126: 364–371.
- 29 Stack WA, Jenkins D, Vivet P, Hawkey CJ. Lack of effectiveness of the platelet-activating factor antagonist SR27417A in patients with active ulcerative colitis: a randomized controlled trial. The Platelet Activating Factor Antagonist Study Group in Ulcerative Colitis. Gastroenterology. 1998; 115: 1340–1345.
- 30 Dhillon AP, Anthony A, Sim R, et al. Mucosal capillary thrombi in rectal biopsies. Histopathology. 1992; 21: 127–133.
- 31 Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001; 85: 430–434.
- 32 Thompson NP, Wakefield AJ, Pounder RE. Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology. 1995; 108: 1011–1015.
- 33 Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 1998; 101: 877–889.
- 34 Walsh RL, Dillon TJ, Scicchitano R, McLennan G. Heparin and heparan sulphate are inhibitors of human leucocyte elastase. Clin Sci (Lond). 1991; 81: 341–346.
